TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06511583

Intervention type: PROCEDURE
Intervention: Laryngotracheal Aspiration Procedure Using a Probe in the Emergency Department
Description: For laryngotracheal aspiration using a blind probe, the patient will be positioned in a seated or semi-seated position; if this is not possible, the aspiration will be performed in a supine position. A soft, sterile catheter connected to the suction apparatus will be inserted into one nostril while keeping the patient\&#39;s head tilted back. When the tip of the catheter reaches the back of the pharynx, the patient will need to breathe to facilitate the insertion and allow the catheter to advance into the larynx and trachea. At this point, using negative suction pressure for a maximum of 3-5 seconds, the secretions will be aspirated. The aspiration will be repeated multiple times in cycles of 3-5 seconds.

Intervention type: PROCEDURE
Intervention: Aspiration Procedure Using Fibrobronchoscopy in the Emergency Department
Description: Equipment Setup:~A sterile bronchoscope will be connected to the suction apparatus.~Procedure:~The bronchoscope will be gently inserted through the patient\&#39;s nostril or mouth, advancing carefully through the pharynx and larynx into the trachea and bronchi.~The physician will visually inspect the airways through the bronchoscope. Using the bronchoscope's suction channel, secretions will be aspirated from the trachea and bronchi.~Suctioning will be performed intermittently to avoid hypoxia, with each suctioning cycle lasting no more than 3-5 seconds.~The procedure may be repeated as necessary to ensure thorough aspiration of secretions.
Study: NCT05829837

Intervention type: OTHER
Intervention: Ultrasonographic evaluation
Description: Ultrasonographic evaluation for the thickness of piriformis muscle

Intervention type: OTHER
Intervention: Ultrasonographic evaluation
Description: Ultrasonographic evaluation for the thickness of piriformis muscle
Study: NCT05958602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology
Description: See previous response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard DSMES Only
Description: See previous response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Recruitment Methods
Description: See previous response.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW-Led Recruitment Methods
Description: See previous response.
Study: NCT06157073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop ventilator
Description: Fully automated closed-loop ventilator using the INTELLIVENT software

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop ventilator
Description: Conventional closed-loop ventilator with manual adjustments by the physician in charge
Study: NCT06442982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insole-type gait analyzer
Description: Patients with subjective gait and balance disorders will wear insole-type gait analyzer and walk, then the collected data will be examined.
Study: NCT05505799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intubation Checklist
Description: A preprocedure checklist will be made available to clinicians, and they will be educated on proper use of the checklist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Clinicians will intubate as per their usual practice
Study: NCT04893213

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation of availability of lower energy meal options
Description: Menus provided differ in % of menu options that are higher vs. lower in energy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation of availability of lower energy meal options
Description: Menus provided differ in % of menu options that are higher vs. lower in energy
Study: NCT05353517

Intervention type: DEVICE
Intervention: Device: focal muscle vibration and theta burst stimulation
Description: non invasive techniques of neuromodulation for inducing plasticity in M1 and spinal cord

Intervention type: DEVICE
Intervention: Device: focal muscle vibration and theta burst stimulation
Description: non invasive techniques of neuromodulation for inducing plasticity in M1 and spinal cord
Study: NCT06093217

Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: AI technology will generate a report with relevant key slice imaging identifying the presence of an acute pulmonary embolism and RV:LV ratio measurements to the radiologist

Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: AI technology will generate a report with relevant key slice imaging identifying the presence of an acute pulmonary embolism and RV:LV ratio measurements to the radiologist
Study: NCT06014710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallowing evaluation
Description: For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.~For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)
Study: NCT04774341

Intervention type: DRUG
Intervention: anticoagulation treatment
Description: Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation

Intervention type: DRUG
Intervention: anticoagulation treatment
Description: Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
Study: NCT04911465

Intervention type: DEVICE
Intervention: Flashback CRI T1 Tablet
Description: Collect continuous data on the compensatory reserve index, a measurement of a patient's central volume status.
Study: NCT04677855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCUR-101
Description: 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCUR-101
Description: 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCUR-101
Description: 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCUR-101
Description: 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Description: 0.5 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone and Prednisone
Description: 500 mg tablets Abiraterone with 5 mg Prednisone Tablets
Study: NCT05750147

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Blood for DNA and biomarker analysis
Study: NCT06615882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent-angioplasty & nimodipine infusion (During the stent (Solitaire-X) -angioplasty, IA nimodipine was also infused)
Description: I. Procedure \& Intervention~1. Assess the presence and degree of cerebral vasospasm of the target vessel through cerebral angiography before the procedure.~2. Solitaire-X stent types are selected~3. During the stent-angioplasty, IA nimodipine was also infused.~4. Retrieve Solitaire-X after maintaining deployment for 3 minutes.~5. Additional procedures are determined through immediate post-procedure and 15-minute delayed cerebral angiography.
Study: NCT06616012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neosense umbilical catheter
Description: The Neosense umbilical catheter is used instead of a standard umbilical catheter
Study: NCT06616350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: esTOCma: an app to fight stigma associated with OCD
Description: The intervention consists of playing a serious game, called esTOCma, on a mobile phone. In the game, players must use their knowledge to battle the stigma monster of OCD, complete 10 missions, and release 10 individuals who have been afflicted by the esTOCma monster, a creature that feeds on false beliefs and misinformation in society.
Study: NCT06617780

Intervention type: RADIATION
Intervention: X-ray (wrist)after 3 months and CT (wrist) the day after closed reduction
Description: One addition x-ray and on addition CT scan of the wrist
Study: NCT03432065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
Study: NCT06502587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood flow restriction training
Description: we will apply blood flow restriction training with low intensity exercises like knee flexion ,knee extension and straight leg raise 10 repetitions 2 sets a day and 3 times/week a rest interval of 2 minutes between exercises, for 30 minutes of this whole procedure.~total 12 sessions given in 4 weeks each session of maximum 30 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound therapy
Description: All subjects will be given Ultrasound therapy as per patient requirement with 1.5 Watts/cm\^2 in continuous mode around knee joint. Conservative exercises(quads isometric exercise, pillow squeeze, heel raise, straight leg raise and side leg raise) will be applied for 3 times per week (daily one set of 10 repetitions) They will be given this treatment for 3 times per week
Study: NCT05284812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
Description: Subjects receive low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
Description: Subjects receive low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
Description: Subjects receive high-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
Description: Subjects receive high-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
Description: Subjects receive high-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
Description: Subjects receive high-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo
Description: Subjects receive Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo injection into the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo
Description: Subjects receive Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo injection into the deltoid muscle of the upper arm
Study: NCT06390943

Intervention type: OTHER
Group type: OTHER
Intervention: Facility-based feeding support package plus (FB-FSP+)
Description: Package of materials to support facility-based feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides

Intervention type: OTHER
Group type: OTHER
Intervention: Transition-to-home feeding support package plus (TTH-FSP+)
Description: Package of materials to support transition-to-home feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
Study: NCT05919017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone implant
Description: Naltrexone implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone implant
Description: Naltrexone implant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05263115

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise intervention
Description: 12-week progressive resistance exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional stair climbing and stepping-based exercise intervention
Description: 12-week progressive stair climbing and stepping-based exercise intervention
Study: NCT06318104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan
Description: Tegoprazan 50 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole 40 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
Study: NCT06259474

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hypopressive Exercises and (heat therapy, medication, and progressive strength training)
Description: 20 subjects combined HE with traditional treatments for LBP (heat therapy, medication, and progressive strength training). Each session consisted of 5 to 10 HEs. Participants were instructed not to hold their breath or perform PFMS contractions during the HEs. Traditional treatment for low back pain typically involved using medications like acetaminophen (0.5-1 g three times daily) and heat therapy, which consisted of using a continuous heat wrap for 2 hours, 3 times per week at 40 °C, one hour before and after the session

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hypopressive Exercises and (heat therapy, medication, and progressive strength training)
Description: 20 subjects combined HE with traditional treatments for LBP (heat therapy, medication, and progressive strength training). Each session consisted of 5 to 10 HEs. Participants were instructed not to hold their breath or perform PFMS contractions during the HEs. Traditional treatment for low back pain typically involved using medications like acetaminophen (0.5-1 g three times daily) and heat therapy, which consisted of using a continuous heat wrap for 2 hours, 3 times per week at 40 °C, one hour before and after the session
Study: NCT05172388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air purifier
Description: Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Air purifier
Description: Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).
Study: NCT04878198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jogging program
Description: This intervention consists of 50 sessions of morning jogging sessions at moderate intensity level. Each intervention session will be administered by a trained research assistant assisted by student helpers. All the research staff (i.e. student helpers and research assistant) will be required to attend a workshop (see educational plan) to standardize the procedure on implementing the intervention, as well as handling and motivating their ASD partners. Motivation techniques in previous protocol will be used to enhance the compliance rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jogging program
Description: This intervention consists of 50 sessions of morning jogging sessions at moderate intensity level. Each intervention session will be administered by a trained research assistant assisted by student helpers. All the research staff (i.e. student helpers and research assistant) will be required to attend a workshop (see educational plan) to standardize the procedure on implementing the intervention, as well as handling and motivating their ASD partners. Motivation techniques in previous protocol will be used to enhance the compliance rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin supplement intervention
Description: This intervention is a 10-week melatonin supplement intervention where melatonin supplement will be provided 30 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin supplement intervention
Description: This intervention is a 10-week melatonin supplement intervention where melatonin supplement will be provided 30 minutes before bedtime.
Study: NCT05124847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants will receive nutritional education sessions and will be instructed to maintain an intake window of at least 13 hours a day, preferably every day of the week and in any case at least 6 days a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants will receive nutritional education sessions and will be instructed to maintain an intake window of at least 13 hours a day, preferably every day of the week and in any case at least 6 days a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: A personalized progression will be established to progressively reduce the intake window during the first 10 days of intervention. After these first 10 days, the participants will be prescribed to limit food intake to a maximum of 10 hours a day, at least 5 days a week. Participant can freely select the time of day to place the intake window. However, it will be recommended to avoid making the last intake in the 3 hours before going to bed. After 4 weeks of intervention, the dietitian will invite them to reduce the intake window to 9 or 8 hours, if they consider it feasible, maintaining this new intake window during the last 4 weeks of intervention. The intake window can be maintained at 10 hours until the end of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: A personalized progression will be established to progressively reduce the intake window during the first 10 days of intervention. After these first 10 days, the participants will be prescribed to limit food intake to a maximum of 10 hours a day, at least 5 days a week. Participant can freely select the time of day to place the intake window. However, it will be recommended to avoid making the last intake in the 3 hours before going to bed. After 4 weeks of intervention, the dietitian will invite them to reduce the intake window to 9 or 8 hours, if they consider it feasible, maintaining this new intake window during the last 4 weeks of intervention. The intake window can be maintained at 10 hours until the end of the study.
Study: NCT06130852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training
Description: 10 thematic sessions aimed at changing the parent's view of their child by encouraging them to focus on appropriate behaviors. The sessions focus on specific themes such as positive attention, the principle of reinforcement, or even homework management.
Study: NCT05380934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3821 tablets
Description: TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3821 tablets
Description: TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3821 tablets
Description: TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3821 tablets
Description: TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH3821 tablets (Placebo)
Description: TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH3821 tablets (Placebo)
Description: TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH3821 tablets (Placebo)
Description: TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH3821 tablets (Placebo)
Description: TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate tablets
Description: Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate tablets
Description: Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition